Question Bank › Event-dense runway

Event-dense runway

Event-dense runway: management frames the coming quarters as a calendar of its own named, scheduled events

Calls Tested
422
Answered YES
22
Hit Rate
5.2%
rare by design

FormFactor, Inc. (FORM) — this company's answers

NO on the Q4 2021 call 2022-02-02 B
The model's full reasoning — Q4 2021 call → NO我们根据提供的财报电话会议记录,判断管理层是否将近期未来(未来几个季度)视为公司自身特定、已命名、已安排的事件日历,并将该事件序列作为公司未来走向的核心叙事。 分析管理层的前瞻性讨论: - 管理层提到了“新Livermore制造中心”在第四季度开始出货,并逐步增加产能。 - 提到了“工程系统业务”的持续需求,以及“FRT光学计量工具”在先进封装应用中的采用。 - 提到了“HPD低温测试工具和服务”的新项目,用于量子计算开发。 - 提到了“产能扩张”和“其他设施的扩展”。 - 提到了“2022年资本支出计划”在6000万至8000万美元之间。 - 提到了“第一季度展望”中的季节性下降和供应链/劳动力限制。 但关键问题是:管理层是否将多个具体的、已命名的、时间锚定的公司特定事件作为未来几个季度的主要叙事?管理层确实提到了几个具体事件:Livermore制造中心的启动和产能提升、HPD低温测试服务的新项目、以及持续的产能扩张。这些事件都有时间框架(例如,第四季度开始出货,逐步增加产能;新项目已启动)。然而,这些事件是否构成一个“日历”,即多个不同的事件按时间顺序排列,并且管理层将处理该事件序列作为公司未来走向的核心? 管理层在回答中提到了这些事件,但整体前瞻性讨论更多是关于需求、市场条件、供应链和劳动力挑战。例如,他们讨论了“Foundry和Logic探针卡”的需求、DRAM需求、系统业务的需求,以及供应链和劳动力问题。他们提到了“第一季度展望”中的季节性下降和约束。虽然他们提到了Livermore和HPD,但这些似乎不是作为未来几个季度的主要事件日历,而是作为背景或正在进行的举措。 此外,管理层没有明确列出未来几个季度的具体事件时间表,如“本季度”、“下季度”、“年中”等。他们提到“在第四季度开始出货”和“逐步增加产能”,但这是过去的事件。对于未来,他们提到“2022年资本支出计划”和“第一季度展望”,但这不是一个事件日历。 因此,前瞻性讨论主要围绕市场条件、需求趋势、供应链和劳动力问题,而不是围绕公司自身的一系列具体事件。虽然有一些具体事件(如Livermore和HPD),但这些不是作为未来几个季度的主要叙事,而是作为正在进行的举措。 因此,答案应为NO。

← Back to the full FORM analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that event sequence as the central story of where the company is heading? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent posture: the forward-looking discussion is organized around MULTIPLE distinct, concrete happenings that belong to the company itself and are expected to occur soon — each one identifiable and time-anchored in management's telling (this quarter, next quarter, by mid-year, this season, in the coming months). The events may take whatever form fits the industry — for example: a facility, line, site, store format, or capacity starting up or opening; a product, program, service, or offering launching or shipping; a ramp, rollout, or expansion beginning or reaching its next stage; a first delivery, first production, first cohort, or go-live; a submission, decision, certification, data readout, or approval date; a contract, program, or partnership commencing; a new market or channel switching on. What matters is that (a) there are SEVERAL such distinct company-specific events, not just one; (b) management anchors them in the near term with at least rough timing, presenting them as scheduled or in motion rather than aspirational; and (c) management treats this sequence of upcoming events — rather than general market conditions, demand trends, or cost management — as the main engine of the company's next stage, with the call's forward energy devoted to what is about to happen and how the company is preparing for each step. Answer NO if the forward discussion is chiefly about market conditions, demand strength or weakness, macro factors, pricing, or cost control, with no calendar of company-specific events. NO if there is only ONE meaningful upcoming event, however large. NO if the future items are vague ambitions, pipeline hopes, exploratory initiatives, or opportunities without stated near-term timing. NO if the named events are routine recurring housekeeping this business always has (ordinary seasonal openings at the usual pace, standard annual product refreshes, scheduled maintenance) that management does not present as changing the company's trajectory. NO if management mentions upcoming milestones only in passing while the call's substance is defending current results. NO if the events are mainly things happening TO the company from outside (market recoveries, customer budget cycles, industry conditions) rather than the company's own scheduled actions. NO if the event calendar appears only in an analyst's question or summary that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
RCEL AVITA Medical, Inc. Q1 2024 2024-05-14 F
ERO Ero Copper Corp. Q1 2024 2024-05-10 A
LILA Liberty Latin America Ltd. Q4 2023 2024-02-23 C
BRBR BellRing Brands, Inc. Q4 2023 2023-11-21 B+
SBS Companhia de Saneamento Básico do Estado Q3 2023 2023-11-10 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
NBTX Nanobiotix S.A. Q2 2023 2023-09-27 D
PTLO Portillo's Inc. Q2 2023 2023-08-05 B
BEAT BioTelemetry's Q4 2022 2023-03-17 D
ARWR Arrowhead Pharmaceuticals, Inc. Q4 2022 2022-11-28 D
FLL Full House Resorts, Inc. Q3 2022 2022-11-07 B
ASTS AST SpaceMobile, Inc. Q2 2022 2022-08-15 D
HROW Harrow Health, Inc. Q4 2021 2022-03-10 C
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
ALKS Alkermes plc Q3 2018 2018-10-23 C
AU AngloGold Ashanti's Q2 2018 2018-08-20 B
ITCI Intra-Cellular Therapies, Inc. Q4 2017 2018-03-01 D
PCRX Pacira BioSciences, Inc. Q4 2017 2018-02-28 C
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
FATE Fate Therapeutics, Inc. Q3 2016 2016-11-07 C
DUK Duke Energy Corporation Q2 2016 2016-08-04 B

How the model reasoned

PCRX · Q4 2017 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management frames the near-term outlook (2018) as a concrete calendar of its own named, time-anchored events—nerve-block label expansion, C-section study readout, additional Phase 4 study launches, CMS reimbursement decisions, and new partnerships—treating the execution of this sequence as the primary driver of 2018 growth and strategic progress. These are presented as scheduled company actions rather than general market trends, with explicit timing (e.g., mid-year FDA meetings, second-half manufacturing ramp, AAOS programs) and positioned as the central story of where the company is heading.
AU · Q2 2018 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management structures the forward outlook around a clear sequence of its own named, time-anchored events—Kibali underground ramp-up and Azambi hydropower station (Q3), Siguiri CIL circuit and power plants (Q4), Obuasi redevelopment milestones (first gold end-2019), Mponeng 6-month backfill plant start (H2), South Africa Section 189 process and wage negotiations (Q3), plus production upticks at multiple sites—presenting these as the primary drivers of the next stage rather than generic market or cost themes.
HROW · Q4 2021 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES The transcript shows management organizing the near-term outlook around a clear sequence of its own named, time-anchored events: AMP-100 PDUFA on October 16 (with launch a few months later), Surface Opthalmics data readout in a few months, Melt Pharmaceuticals top-line data soon after, and internal product 18-month launches, plus MAQ-100 FDA meeting mid-year and relaunch preparations for IOPIDINE/MAXITROL/MOXEZA.

More from the question bank

Second engine igniting off the firstManagement is buying/committing capital at aThe leak is fixed: the company is keeping whDemand pull is outrunning the plan for one sBet-the-company financing already spent on hSaid-then-did: management reports back on itAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.